Contribute
España
Italia
대한민국
日本
Français
Benzinga
Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
757.530.04%
QQQ
706.900.25%
BTC/USD
76876.700.4474%
DIA
520.830.02%
GLD
395.600.19%
TLT
80.750.04%

Protagonist Therapeutics Inc

PTGXNASDAQ
Trade with Public
Trade with Public
$145.16
0.070.05%
At close: Sep 10, 5:00 PM EST
$145.16
N/A
After Hours: 4:00 PM EST
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompareOptionsStock Report

Protagonist Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Protagonist Therapeutics (PTGX).

Price Target Range — 13 Quarters

Analyst Consensus — 17 Analysts

3S.Buy
14Buy
Consensus RatingBuy# Analysts17Avg. Consensus PT$129Upside to Avg. PT-11.3%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →
DateFirmAnalystActionRating ChangePrice Target
Sep 1, 2026BarclaysEtzer DaroutPT RaiseOverweight$153→$180
Sep 1, 2026BMO CapitalEtzer DaroutPT RaiseOutperform$178→$190
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Barclays Maintains Overweight on Protagonist Therapeutics, Raises Price Target to $180

Barclays analyst Etzer Darout maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Overweight and raises the price target from $153 to $180.
Benzinga Newsdesk

Apple To $303? Here Are 10 Top Analyst Forecasts For Tuesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Cantor Fitzgerald raised
Avi Kapoor

PRO
BMO Capital Maintains Outperform on Protagonist Therapeutics, Raises Price Target to $190

BMO Capital analyst Etzer Darout maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Outperform and raises the price target from $178 to $190.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Protagonist Therapeutics, Raises Price Target to $170

HC Wainwright & Co. analyst Douglas Tsao maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Buy and raises the price target from $167 to $170.
Benzinga Newsdesk

PRO
BMO Capital Maintains Outperform on Protagonist Therapeutics, Raises Price Target to $178

BMO Capital analyst Etzer Darout maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Outperform and raises the price target from $112 to $178.
Benzinga Newsdesk

PRO
Truist Securities Maintains Buy on Protagonist Therapeutics, Raises Price Target to $170

Truist Securities analyst Srikripa Devarakonda maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Buy and raises the price target from $145 to $170.
Benzinga Newsdesk

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved